PF-04254644

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H17N7
Molecular Weight	355.3959
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](C1=NN=C2C=CC(=NN12)C3=CN(C)N=C3)C4=CC=C5N=CC=CC5=C4

InChI

InChIKey=VQYHPUHKYSSEOB-ZDUSSCGKSA-N

InChI=1S/C20H17N7/c1-13(14-5-6-17-15(10-14)4-3-9-21-17)20-24-23-19-8-7-18(25-27(19)20)16-11-22-26(2)12-16/h3-13H,1-2H3/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H17N7
Molecular Weight	355.3959
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 17:31:49 GMT 2025` Edited by `admin` on `Wed Apr 02 17:31:49 GMT 2025`
Record UNII	UN4C7N5KVB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PF-04254644

Common Name

English

(S)?6-(1-(6-(1-Methyl?1H?pyrazol-4-yl)-[1,2,4]triazolo[4,3?b]pyridazin-3-yl)ethyl)quinoline

Preferred Name

English

Quinoline, 6-[(1S)-1-[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]ethyl]-

Systematic Name

English

6-[(1S)-1-[6-(1-Methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]ethyl]quinoline

Systematic Name

English

Code System Code Type Description

FDA UNII

UN4C7N5KVB

Created by admin on Wed Apr 02 17:31:49 GMT 2025 , Edited by admin on Wed Apr 02 17:31:49 GMT 2025

PRIMARY

PUBCHEM

24871823

Created by admin on Wed Apr 02 17:31:49 GMT 2025 , Edited by admin on Wed Apr 02 17:31:49 GMT 2025

PRIMARY

CAS

959584-91-9

Created by admin on Wed Apr 02 17:31:49 GMT 2025 , Edited by admin on Wed Apr 02 17:31:49 GMT 2025

PRIMARY

Related Record Type Details


					FMS08T2916

CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					M8G1X4M9U1

CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					JOC85XIO65

CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE A

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					5AYQ2F6KU4

CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B

OFF-TARGET->INHIBITOR

Comments:

May be responsible for myocarditis and cardiac toxicity

Qualification:

IC50

Amount:


					ZTU32AE62N

CALCIUM/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1A

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					KT6HT14BLU

PHOSPHODIESTERASE 5A, HUMAN

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					TZV29E2PUX

CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4C

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					1R38R691S2

CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					U2Z67D3AHF

CALCIUM/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1C

OFF-TARGET->INHIBITOR

Qualification:

IC50

Amount:


					EX5YF58MG8

6-[(1R)-1-[6-(1-Methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]ethyl]quinoline

ENANTIOMER -> ENANTIOMER

Amount:


					QA085PMU8Q

HEPATOCYTE GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Qualification:

IC50

Amount: